FDA releases anthrax blood donor guidance:
This article was originally published in Clinica
The FDA has issued a guidance document to help industry determine the suitability of blood donors who have been potentially exposed to anthrax. The guidance document, announced in the Federal Register of January 14, applies to whole blood and blood components, including recovered plasma and source plasma collections intended for use in transfusion or for further manufacturing into injectable products. Although the FDA is soliciting public comment, it will implement the guidance document immediately due to public health concerns.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.